相似文献
1
Chromosome 9p and 10q losses predict unfavorable outcome in low-grade gliomas.
Neuro Oncol. 2010 Jan;12(1):2-6. doi: 10.1093/neuonc/nop002. Epub 2009 Oct 15.
2
Loss of 1p, 19q, and 10q heterozygosity prospectively predicts prognosis of oligodendroglial tumors--towards individualized tumor treatment?
Neuro Oncol. 2010 May;12(5):490-9. doi: 10.1093/neuonc/nop071. Epub 2010 Feb 14.
3
Prognostic stratification of patients with anaplastic gliomas according to genetic profile.
Cancer. 2006 Oct 15;107(8):1891-7. doi: 10.1002/cncr.22211.
4
Loss of heterozygosity on chromosomes 10q, 9p, 17p and 13q in malays with malignant glioma.
Neurol Res. 2004 Jan;26(1):88-92. doi: 10.1179/016164104773026598.
5
Contribution of 1p, 19q, 9p and 10q Automated Analysis by FISH to the Diagnosis and Prognosis of Oligodendroglial Tumors According to WHO 2016 Guidelines.
PLoS One. 2016 Dec 28;11(12):e0168728. doi: 10.1371/journal.pone.0168728. eCollection 2016.
6
Loss of heterozygosity for loci on chromosome arms 1p and 10q in oligodendroglial tumors: relationship to outcome and chemosensitivity.
J Neurooncol. 2003 Sep;64(3):271-8. doi: 10.1023/a:1025689004046.
7
Loss of 22q chromosome is related to glioma progression and loss of 10q.
J Neurooncol. 2006 Feb;76(3):265-8. doi: 10.1007/s11060-005-7019-2.
8
Molecular heterogeneity of oligodendrogliomas suggests alternative pathways in tumor progression.
Neurology. 2001 Oct 9;57(7):1278-81. doi: 10.1212/wnl.57.7.1278.
9
Analysis of 1p, 19q, 9p, and 10q as prognostic markers for high-grade astrocytomas using fluorescence in situ hybridization on tissue microarrays from Radiation Therapy Oncology Group trials.
Neuro Oncol. 2004 Apr;6(2):96-103. doi: 10.1215/s1152851703000231.
10
Clinical relevance of 1p and 19q deletion for patients with WHO grade 2 and 3 gliomas.
J Neurooncol. 2008 Jul;88(3):293-8. doi: 10.1007/s11060-008-9563-z. Epub 2008 Mar 15.
引用本文的文献
1
Adolescent and young adult glioma: systematic review of demographic, disease, and treatment influences on survival.
Neurooncol Adv. 2022 Oct 22;4(1):vdac168. doi: 10.1093/noajnl/vdac168. eCollection 2022 Jan-Dec.
2
The Role of Neurodevelopmental Pathways in Brain Tumors.
Front Cell Dev Biol. 2021 Apr 27;9:659055. doi: 10.3389/fcell.2021.659055. eCollection 2021.
3
Transcription factors NFIA and NFIB induce cellular differentiation in high-grade astrocytoma.
J Neurooncol. 2020 Jan;146(1):41-53. doi: 10.1007/s11060-019-03352-3. Epub 2019 Nov 23.
4
Integrated systems-genetic analyses reveal a network target for delaying glioma progression.
Ann Clin Transl Neurol. 2019 Sep;6(9):1616-1638. doi: 10.1002/acn3.50850. Epub 2019 Aug 17.
5
Machine Learning Versus Logistic Regression Methods for 2-Year Mortality Prognostication in a Small, Heterogeneous Glioma Database.
World Neurosurg X. 2019 Jan 24;2:100012. doi: 10.1016/j.wnsx.2019.100012. eCollection 2019 Apr.
6
Updates in prognostic markers for gliomas.
Neuro Oncol. 2018 Nov 9;20(suppl_7):vii17-vii26. doi: 10.1093/neuonc/noy158.
7
A clinical perspective on the 2016 WHO brain tumor classification and routine molecular diagnostics.
Neuro Oncol. 2017 May 1;19(5):614-624. doi: 10.1093/neuonc/now277.
8
Contribution of 1p, 19q, 9p and 10q Automated Analysis by FISH to the Diagnosis and Prognosis of Oligodendroglial Tumors According to WHO 2016 Guidelines.
PLoS One. 2016 Dec 28;11(12):e0168728. doi: 10.1371/journal.pone.0168728. eCollection 2016.
9
Loss of Heterozygosity of 9p Is Associated with Poorer Survival in Patients with Gliomas.
Mol Neurobiol. 2016 Nov;53(9):6407-6412. doi: 10.1007/s12035-015-9523-5. Epub 2015 Nov 19.
10
Molecular Markers in Low-Grade Glioma-Toward Tumor Reclassification.
Semin Radiat Oncol. 2015 Jul;25(3):155-63. doi: 10.1016/j.semradonc.2015.02.006. Epub 2015 Feb 23.
本文引用的文献
1
Genomic changes in progression of low-grade gliomas.
J Neurooncol. 2008 Nov;90(2):133-40. doi: 10.1007/s11060-008-9644-z. Epub 2008 Jul 11.
2
Clinical relevance of 1p and 19q deletion for patients with WHO grade 2 and 3 gliomas.
J Neurooncol. 2008 Jul;88(3):293-8. doi: 10.1007/s11060-008-9563-z. Epub 2008 Mar 15.
3
Temozolomide for low-grade gliomas: predictive impact of 1p/19q loss on response and outcome.
Neurology. 2007 May 22;68(21):1831-6. doi: 10.1212/01.wnl.0000262034.26310.a2.
4
Identification of genomic aberrations associated with shorter overall survival in patients with oligodendroglial tumors.
Int J Cancer. 2007 Jun 1;120(11):2368-76. doi: 10.1002/ijc.22574.
5
A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma.
Cancer Res. 2006 Oct 15;66(20):9852-61. doi: 10.1158/0008-5472.CAN-06-1796.
6
Prognostic stratification of patients with anaplastic gliomas according to genetic profile.
Cancer. 2006 Oct 15;107(8):1891-7. doi: 10.1002/cncr.22211.
7
Loss of heterozygosity 1p36 and 19q13 is a prognostic factor for overall survival in patients with diffuse WHO grade 2 gliomas treated without chemotherapy.
J Clin Oncol. 2006 Oct 10;24(29):4758-63. doi: 10.1200/JCO.2006.05.9238. Epub 2006 Sep 11.
8
Prognostic impact of molecular markers in a series of 220 primary glioblastomas.
Cancer. 2006 May 15;106(10):2218-23. doi: 10.1002/cncr.21819.
9
Survival rates and patterns of care for patients diagnosed with supratentorial low-grade gliomas: data from the SEER program, 1973-2001.
Cancer. 2006 Mar 15;106(6):1358-63. doi: 10.1002/cncr.21733.
10
Chromosome 1p loss: a favorable prognostic factor in low-grade gliomas.
Ann Neurol. 2005 Aug;58(2):322-6. doi: 10.1002/ana.20543.
Zotero 插件